Characterization of adaptive anti-tumor immune responses in our cohorts of patients was carried out by IFN-γ ELISPOT assay of spontaneous CD8+ T cell responses to 13 HLA-A*0201-restricted peptides derived from 6 different TAA (Mammaglobin-A, Survivin, Muc-1, HER2, Trag-3, Bcl-xL) [28–34] in 6 HER2-positive and 7 HER2-negative patients expressing the HLA-A*0201 allele. This evidence concerns the gene BIRC5 and neoplasm.